SCHEMBL15312867

SCHEMBL15312867

O=C1N(Cc2ccc(C(F)(F)F)o2)c2ccccc2C1(O)c1cc2c(cc1OCc1ccccc1)OCO2

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 17/20 0.60
SCN7A Q01118 1/20 0.60
SCN5A Q14524 1/20 0.60
SCN2A Q99250 1/20 0.60
SCN8A Q9UQD0 1/20 0.60
SCN10A Q9Y5Y9 1/20 0.60
ALDH1A1 P00352 3/20 0.44
USP2 O75604 2/20 0.44
MAPT P10636 2/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
KDM4E B2RXH2 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15316314 0.88 SCN9A (0.59) SCN9ASCN7ASCN5ASCN2ASCN8A
SCHEMBL15312936 0.87 SCN9A (0.57) SCN9ASCN7ASCN5ASCN2ASCN8A
SCHEMBL15312949 0.87 SCN9A (0.57) SCN9ASCN7ASCN5ASCN2ASCN8A
SCHEMBL15313055 0.85 SCN9A (0.67) SCN9ASCN7ASCN5ASCN2ASCN8A
SCHEMBL15314977 0.84 SCN9A (0.66) SCN9ASCN7ASCN5ASCN2ASCN8A
SCHEMBL19734522 0.79 SCN9A (0.60) SCN9ASCN7ASCN5ASCN2ASCN8A
SCHEMBL19734523 0.79 SCN9A (0.60) SCN9ASCN7ASCN5ASCN2ASCN8A
SCHEMBL15312943 0.77 SCN9A (0.47) SCN9ASCN7ASCN5ASCN2ASCN8A
SCHEMBL3604833 0.77 SCN9A (0.59) SCN9ASCN7ASCN5ASCN2ASCN8A
SCHEMBL19734405 0.76 SCN9A (0.58) SCN9ASCN7ASCN5ASCN2ASCN8A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2838902-B1 ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2018-12-05 EP disclosed
US-20170066777-A1 ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2017-03-09 US disclosed
US-20170066777-A1 ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2017-03-09 US disclosed
US-9487535-B2 Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2016-11-08 US disclosed
EP-2838902-A1 ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS Xenon Pharmaceuticals Inc. (CA) 2015-02-25 EP disclosed
WO-2013154712-A1 ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2013-10-17 WO disclosed
US-20130274483-A1 ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS PACIRA PHARMACEUTICALS, INC. 2013-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170066777-A1 ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS OPRK1, OPRL1, PKD2 SCN9A 51/4885SCN7A 29/4885SCN5A 22/4885
US-20130274483-A1 ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS OPRK1, OPRL1, PKD2 SCN9A 51/4885SCN7A 29/4885SCN5A 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.